ImageneBio (NASDAQ:IMA) Announces Earnings Results

ImageneBio (NASDAQ:IMA) posted its quarterly earnings results on Wednesday. The company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($1.44), FiscalAI reports.

ImageneBio Trading Down 1.0%

IMA stock traded down $0.09 during mid-day trading on Wednesday, hitting $8.52. 26,925 shares of the company were exchanged, compared to its average volume of 28,562. The firm has a fifty day simple moving average of $8.36 and a 200 day simple moving average of $12.79. ImageneBio has a twelve month low of $7.24 and a twelve month high of $23.28. The company has a market capitalization of $34.17 million, a PE ratio of -1.11 and a beta of 0.42.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Wall Street Zen raised shares of ImageneBio to a “hold” rating in a report on Friday, September 26th. Weiss Ratings began coverage on ImageneBio in a research report on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. Zacks Research cut ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Leerink Partners initiated coverage on ImageneBio in a research note on Friday, October 24th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Wedbush dropped their price objective on ImageneBio from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aldebaran Capital LLC bought a new position in ImageneBio during the first quarter worth $317,000. Vanguard Group Inc. bought a new position in ImageneBio in the 3rd quarter valued at $1,902,000. BML Capital Management LLC bought a new stake in ImageneBio during the 3rd quarter worth about $1,487,000. XTX Topco Ltd raised its position in ImageneBio by 350.6% in the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after purchasing an additional 43,924 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in ImageneBio by 62.4% in the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after acquiring an additional 29,369 shares during the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.